GENOZOL is a Oral Capsule, Delayed Release in the Human Otc Drug category. It is labeled and distributed by Genomma Lab Usa Inc. The primary component is Esomeprazole Magnesium Dihydrate.
Product ID | 50066-923_2a857d32-6752-4c03-b974-89417d192745 |
NDC | 50066-923 |
Product Type | Human Otc Drug |
Proprietary Name | GENOZOL |
Generic Name | Esomeprazole Magnesium |
Dosage Form | Capsule, Delayed Release |
Route of Administration | ORAL |
Marketing Start Date | 2017-10-16 |
Marketing Category | ANDA / ANDA |
Application Number | ANDA209339 |
Labeler Name | Genomma Lab USA Inc |
Substance Name | ESOMEPRAZOLE MAGNESIUM DIHYDRATE |
Active Ingredient Strength | 20 mg/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2017-10-16 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | ANDA |
Application Number | ANDA209339 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2017-10-16 |
Marketing End Date | 2019-11-22 |
Marketing Category | ANDA |
Application Number | ANDA209339 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2017-10-16 |
Ingredient | Strength |
---|---|
ESOMEPRAZOLE MAGNESIUM DIHYDRATE | 20 mg/1 |
NDC | Brand Name | Generic Name |
---|---|---|
50066-923 | GENOZOL | GENOZOL |
50066-915 | Genozol | Genozol |
0093-6450 | Esomeprazole Magnesium | Esomeprazole Magnesium |
0093-6451 | Esomeprazole Magnesium | Esomeprazole Magnesium |
0186-0382 | Esomeprazole magnesium | Esomeprazole magnesium |
0186-0384 | Esomeprazole magnesium | Esomeprazole magnesium |
0186-4010 | NEXIUM | Esomeprazole magnesium |
0186-4020 | NEXIUM | Esomeprazole magnesium |
0186-4025 | NEXIUM | Esomeprazole magnesium |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
GENOZOL 97844735 not registered Live/Pending |
Genomma Lab Internacional, S.A.B de C.V. 2023-03-17 |
GENOZOL 87021957 5188244 Live/Registered |
Genomma Lab Internacional, S.A.B. de C.V. 2016-05-02 |
GENOZOL 86929122 5130410 Live/Registered |
Genomma Lab Internacional, S.A.B. de C.V. 2016-03-04 |